BREAKTHROUGH IN LAM RESEARCH

BREAKTHROUGH IN LAM RESEARCH
Research known as the MILES Trial reveals that while being treated with the drug, sirolimus (rapamycin), for one year, patients showed  a small but significant improvement in lung function*.  However, significant side effects mean that the pros and cons of treatment with sirolimus have to be considered for individual patients. Continue reading…


Diagnostic Blood Test Can Identify Rare Lung Disease

Researchers at the University of Cincinnati and Cincinnati Children’s Hospital Medical Center have established that a particular blood test can successfully identify lymphangioleiomyomatosis (LAM) in some patients, eliminating the need for surgical lung biopsy to make a diagnosis. These findings are published in the July 6 2010 edition of the journal, CHEST. Continue reading…